SCHEMBL31227586

SCHEMBL31227586

O=C(C=CC1CCCNC1)Nc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK3 P52333 1/20 0.48
▸ MMP1 P03956 5/20 0.48
▸ MMP2 P08253 5/20 0.48
▸ MMP9 P14780 5/20 0.48
▸ MAOB P27338 2/20 0.48
▸ EGFR P00533 1/20 0.48
▸ MAOA P21397 1/20 0.48
▸ TGM2 P21980 1/20 0.41
▸ DEGS1 O15121 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ NFKB1 P19838 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ NFKB2 Q00653 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ RELA Q04206 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ TRPV1 Q8NER1 1/20 0.40
▸ HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31227240 0.99 JAK3 (0.47) JAK3MMP1MMP2MMP9MAOB
SCHEMBL14271872 0.77 ALDH1A1 (0.54) KDM4EMEN1NPC1RAB9AKMT2A
SCHEMBL31369429 0.74 SLC6A1 (0.47) KDM4EKMT2ASMN1; SMN2
Hydrochloric Acid SCHEMBL28947552 0.73 SLC6A1 (0.46) KDM4EKMT2ASMN1; SMN2
SCHEMBL1318173 0.73 HPGD (0.66) JAK3MEN1KMT2ASMN1; SMN2HPGD
SCHEMBL2446479 0.73 HPGD (0.66) JAK3MEN1KMT2ASMN1; SMN2HPGD
SCHEMBL1318166 0.73 HPGD (0.66) JAK3MEN1KMT2ASMN1; SMN2HPGD
Hydrochloric Acid SCHEMBL4033476 0.71 HPGD (0.64) JAK3MEN1KMT2ASMN1; SMN2HPGD
SCHEMBL12260725 0.70 EPHX1 (0.68) JAK3MEN1NPC1RAB9AKMT2A
SCHEMBL816890 0.70 KHK (0.50) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors INITIAL THERAPEUTICS, INC. (US) 2024-12-05 — — US disclosed
WO-2024226875-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS INITIAL THERAPEUTICS, INC. (US) 2024-10-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors MYCBP, MYC, MYCBP2 JAK3 3826/4885MMP1 4028/4885MMP2 2823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback